GEN Exclusives

More »

GEN News Highlights

More »
Mar 6, 2013

Ajinomoto Moves into CDMO Market

  • Ajinomoto agreed to take over Althea Technologies, a contract development and manufacturing organization (CDMO), by acquiring all of the company’s capital stock for $175 million. According to an Ajinomoto official, the CMDO market is estimated at $2.3 billion and double-digit growth is expected.

    “In combining Ajinomoto’s experience in biotechnology, together with Althea's sophisticated technology, experienced personnel, and expertise in cGMP manufacturing, we aspire to expand our business for biopharmaceuticals manufacturing in the U.S. market and strengthen our advanced biomedical businesses,” said Masatoshi Ito, Ajinomoto’s president and CEO.

    This year Ajinomoto has made a number of deals that confirm its keen interest in the biomedical field. Just last week it announced plans to invest approximately $13.9 million to double production capacity for amino acids for use in pharmaceuticals and foods at its subsidiary Shanghai Ajinomoto Amino Acid Co. The expansion is scheduled to come on line in October.

    In February, Ajinomoto Genexine, its joint venture with Genexine Co., reported plans to construct a new plant in the South Korea for cell culture media for biopharmaceutical production. The new plant, which will cost about $30 million, is scheduled to begin full-scale operation in July 2014.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »